This is a working overview of ESI-MS, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-08 and is reviewed periodically as new material appears.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentapeptide | Chain of five amino acid residues |
| Molecular mass | Approximately 712 Da | Consistent with a five-residue chain |
| Receptor target | GHS-R1a | Growth hormone secretagogue receptor |
| Primary action | Growth hormone release | Pituitary somatotroph stimulation |
| Research origin | Developed in the 1990s | Small-peptide secretagogue program |
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
=== Beginning === Most early progress in tissue engineering research was done in the US. This is due to less strict regulations regarding stem cell research and more available funding than in other countries. This leads to the creation of academic startups many of them coming from Harvard or MIT. Examples are BioHybrid Technologies whose founder, Bill Chick, went to Harvard Medical School and focused on the creation of artificial pancreas. Another example would be Organogenesis Inc. whose founder went to MIT and worked on skin engineering products. Other companies with links to the MIT are TEI Biosciences, Therics and Guilford Pharmaceuticals. The renewed interest in biotechnologies in the 1980s leads to many private investors investing in these new technologies even though the business models of these early startups were often not very clear and did not present a path to long term profitability. Government sponsors were more restrained in their funding as tissue engineering was considered a high-risk investment. In the UK the market got off to a slower start even though the regulations on stem cell research were not strict as well. This is mainly due to more investors being less willing to invest in these new technologies which were considered to be high-risk investments. Another problem faced by British companies was getting the NHS to pay for their products. This especially because the NHS runs a cost-effectiveness analysis on all supported products. Novel technologies often do not do well in this respect. In Japan, the regulatory situation was quite different.
=== Dried fruit === Dried fruit is fruit from which the majority of the original water content has been removed, either naturally, through sun drying, or through the use of specialized dryers or dehydrators. Dried fruit has a long tradition of use dating back to the fourth millennium BC in Mesopotamia, and is prized because of its sweet taste, nutritive value, and long shelf life.
Excimer lasers emitting in ultraviolet and vacuum ultraviolet wavelength ranges are widely used in many industries. Argon-fluoride excimer lasers operating at 193 nm are routinely used in integrated circuit production by photolithography. Coherent sources are available down to a wavelength limit around 126 nm, characteristic of the Ar2* excimer laser. Direct UV-emitting laser diodes are available at 375 nm. UV diode-pumped solid state lasers have been demonstrated using cerium-doped lithium strontium aluminum fluoride crystals (Ce:LiSAF), a process developed in the 1990s at Lawrence Livermore National Laboratory. Wavelengths shorter than 325 nm are commercially generated in diode-pumped solid-state lasers. Ultraviolet lasers can also be made by applying frequency conversion to lower-frequency lasers. Ultraviolet lasers have applications in industry (laser engraving), medicine (dermatology, and keratectomy), chemistry (MALDI), free-space optical communication, computing (optical storage), and manufacture of integrated circuits.
The major surviving part of the walls is visible adjacent to the only remaining gateway under the tower of the Church of St John the Baptist. By the mid-14th century Bristol is considered to have been England's third-largest town (after London and York), with an estimated 15–20,000 inhabitants on the eve of the Black Death of 1348–49. The plague inflicted a prolonged demographic setback, with the population estimated at between 10,000 and 12,000 during the 15th and 16th centuries. One of the first great merchants of Bristol was William Canynge. Born c. 1399, he was five times mayor of the town and twice represented it as an MP. He is said to have owned ten ships and employed over 800 sailors. In later life he became a priest and spent a considerable part of his fortune in rebuilding St Mary Redcliffe church, which had been severely damaged by lightning in 1446.
=== GLP-1 agonists === Another popular medication that is used in T2D management are glucagon like peptide 1 (GLP-1) agonists. This class of medication works by mimicking a hormone called glucagon-like peptide which has many effects in the body. One effect of the hormone is that it helps time the release of insulin when patients eat and the blood glucose rises. In addition, it can significantly increase the amount of insulin release. Lastly, the medication also slows down the movement of food through the digestive tract and can increase feeling of fullness while eating, decreasing appetite and weight. These drugs are very effective at controlling T2D and reducing risk of heart attacks, strokes, and other complications due to diabetes. In addition, patients usually lose weight and have improved blood pressure and cholesterol. Common names of these medications include semaglutide (Ozempic and Wegovy), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity). These medications must be injected and are usually injected in the upper arm, thighs or stomach areas. They are usually given once a week but some of the medication can be as frequent as twice daily. The dose is usually started low and tapered gradually. Some of the common side effects of the medication is nausea, vomiting, and diarrhea. Patients with a family history of medullary thyroid cancer or Multiple Endocrine Neoplasia type 2 should not be prescribed the drug as it may increase the risk of developing cancer.
Sources: en.wikipedia.org
== P == P24 – package insert – palliative – palliative care – pancreas – pancreatitis – pancytopenia – pandemic – pap smear – papilloma – parallel track – parasite – parenteral – paresthesia – passive immunity – passive immunotherapy – pathogen – pathogenesis – PBMC – PCP – PCR – Pediatric AIDS Clinical Trial Group (PACTG) – pelvic inflammatory disease – peptide – perianal – perinatal – perinatal transmission – peripheral neuritis – peripheral neuropathy – persistent generalized lymphadenopathy – PGL – phagocyte – phagocytosis – pharmacokinetics – phase I trials – phase II trials – phase III trials – phase IV trials – photosensitivity – PHS – pituitary gland – placebo – placebo controlled study – placebo effect – plasma – plasma cells – platelets – PML – Pneumocystis jiroveci pneumonia (formerly Pneumocystis carinii or PCP) – POL – polymerase – polymerase chain reaction (PCR) – polyneuritis – polypeptide – polyvalent vaccine – post-exposure prophylaxis (PEP) – PPD test – pre-conception counseling – preclinical – precursor cells – prevalence – primary HIV infection – primary isolate – primaquine – proctitis – prodrome – prodrug – progressive multifocal leukoencephalopathy (PML) – prophylactic drug – prophylaxis – protease – protease inhibitors – protease-sparing regimen – proteins – protocol – protozoa – provirus – pruritus – pseudo-Cushing's syndrome – pseudovirion – PUBMED – pulmonary – purified protein derivative (PPD)
. In multi-compartment pharmacokinetics, two operational half-lives are often distinguished: an early distribution (α) half-life governed by redistribution from the central to peripheral compartments, and a later elimination (β) half-life governed by metabolic clearance and excretion. This is used to measure the removal of things such as metabolites, drugs, and signalling molecules from the body. Typically, the biological half-life refers to the body's natural cleansing, the detoxification through liver metabolism and through the excretion of the measured substance through the kidneys and intestines. This concept is used when the rate of removal is roughly exponential. In a medical context, half-life explicitly describes the time it takes for the blood plasma concentration of a substance to halve (plasma half-life) its steady-state when circulating in the full blood of an organism. This measurement is useful in medicine, pharmacology and pharmacokinetics because it helps determine how much of a drug needs to be taken and how frequently it needs to be taken if a certain average amount is needed constantly. By contrast, the stability of a substance in plasma is described as plasma stability. This is essential to ensure accurate analysis of drugs in plasma and for drug discovery. The relationship between the biological and plasma half-lives of a substance can be complex depending on the substance in question, due to factors including accumulation in tissues, protein binding, active metabolites, and receptor interactions.
=== Research parks and commercialization === Tech Parks Arizona is the research park of the University of Arizona. It comprises three primary facilities: the UA Tech Park at Rita Road, the UA Tech Park at The Bridges, and the University of Arizona Center for Innovation (UACI).
Transport Corporation of India Limited is an Indian logistics and supply chain management company headquartered in Gurugram, Haryana, India. It was founded in 1958 by Prabhu Dayal Agarwal at Kolkata, India.
Meat and bone meal Offal (wild canines eat offal as a vital part of their diets) Animal digest Sucrose and/or fructose Animal by-products Less expensive dog foods generally include less meat and more animal by-products and grain fillers. Proponents of a natural diet criticize the use of such ingredients, and point out that regulations allow for packaging that might lead a consumer to believe that they are buying natural food, when, in reality, the food might be composed mostly of ingredients such as those listed above. More expensive dog foods may be made of ingredients suitable for organic products or free range meats. Lamb meal is a popular ingredient. According to the Association of American Feed Control Officials (AAFCO), animal by-products in pet food may include parts obtained from any animals that have died from sickness or disease, provided they are rendered in accordance to law. Cow brains and spinal cords not allowed for human consumption under federal regulation 21CFR589.2000 due to the possibility of transmission of BSE are allowed to be included in pet food intended for non-ruminant animals. In 2003, the AVMA speculated changes might be made to animal feed regulations to ban materials from "4-D" animals – those who enter the food chain as dead, dying, diseased or disabled.
Sources: en.wikipedia.org
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.
In animal studies it showed greater selectivity for growth hormone release, with less effect on cortisol and adrenocorticotropic hormone than compounds such as GHRP-6. This selectivity is one of the most frequently cited features in preclinical literature. Whether the same profile applies in other contexts is not fully established.
The receptor-level events are reasonably well described, but the full range of downstream effects is not. Studies have reported activity in tissues beyond the pituitary, including the gut. How these observations translate across species and conditions remains an open question.
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.